[Skip to Content]
[Skip to Content Landing]
Article
December 1949

AUREOMYCIN THERAPY OF NONPNEUMOCOCCIC AND NONTUBERCULOUS BACTERIAL PULMONARY INFECTIONS

Author Affiliations

Milton Fellow, Harvard Medical School, and Research Fellow, Thorndike Memorial Laboratory; Research Fellow in Medicine, Harvard Medical School, and Research Fellow, Thorndike Memorial Laboratory; Associate Professor of Medicine, Harvard Medical School; Associate Physician, Thorndike Memorial Laboratory, and Chief, Fourth Medical Service, Boston City Hospital BOSTON

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital, and the Department of Medicine, Harvard Medical School.

Arch Intern Med (Chic). 1949;84(6):875-890. doi:10.1001/archinte.1949.00230060032003
Abstract

THE activity of aureomycin includes a wider variety of the known causative agents of pneumonia than that of any of the earlier effective chemicals or antibiotics1. Clinical trials were, therefore, undertaken of the use of aureomycin in all types of nontuberculous pneumonia and other severe acute infections of the respiratory tract that were available for study. In separate communications, we have presented the results of aureomycin treatment in cases of primary atypical (virus) pneumonia,2 in cases of pneumococcic pneumonias3 and in a variety of other cases which includes influenza and other severe acute infections of the respiratory tract and pneumonias in which a likely causative bacterial agent could not be identified.4 In this paper are presented the results of aureomycin therapy in cases of the nonpneumococcic and nontuberculous bacterial infections of the lungs.

MATERIALS AND METHODS 

Selection of Cases.  —Two groups of cases were studied and

×